RICHMOND, Va. -- GastroFISH(TM) is the first tissue-based fluorescence in situ hybridization (FISH) test for the detection of chromosomal anomalies associated with colon cancer.
"We are excited to be the first laboratory to offer GastroFISH for the colon. Using current histological techniques, identifying adenomas with a high risk for progression to cancer is not possible. Multi-target FISH will be helpful in the identification of these adenomas in conjunction with histology," said Junqi Qian, M.D., Director of Molecular Diagnostics at Bostwick Laboratories(R).
GastroFISH(TM) is a diagnostic test with a high sensitivity and specificity that will aid in the differential diagnosis of adenoma from adenocarcinoma. The results from GastroFISH(TM) together with a pathology diagnosis will assist the physician in guiding a more effective treatment plan for his/her patient.
Gastrocor(R), a division of Bostwick Laboratories(R), is a full service laboratory specializing in gastrointestinal pathology. Headquartered in Richmond, VA, Bostwick Laboratories(R) features an exceptional staff of board certified pathologists dedicated to the diagnosis, and management of prostate cancer, kidney disease, gynecological and urological conditions. The company has additional laboratories in Uniondale, NY, Orlando, FL, Phoenix, AZ, Nashville, TN and London, England.
Copyright 2009, Gastrocor
We care about your feedback. Let us know how we can improve your CancerCompass experience.